



US AWARD FOR STARPHARMA ASSOCIATE DNT INC.

MELBOURNE, 8 OCTOBER 2003: Starpharma Pooled Development Limited (ASX: SPL) has been advised of the following announcement by The University of Central Michigan (CMU):

“CMU-BRED FIRM GETS STATE AWARD -- Mt. Pleasant-based Dendritic Nanotechnologies, Inc. has won the Michigan and Investment and Commercialization Success Award from the Michigan Economic Development Corp. The award recognizes innovation, marketplace success and contributions to the State's economy. DNT opened at Central Michigan University's Center for Applied Research in August 2001. The company manufactures dendrimer molecules, which are used in a variety of advanced applications. The company has received US\$2.9 million from the Army Research Laboratory for its work.”

DNT Ltd was established in 2001 as a partnership between Starpharma and the US pioneer of Dendrimer nanotechnology, Dr Donald Tomalia. It was converted from an Australian incorporated company to the US entity, DNT, Inc., in March 2003. The University of Central Michigan has provided considerable support for the company and together they have established the Dendritic Nanotechnology Center of Excellence at Central Michigan University.

Starpharma invested US\$2.18 million to establish DNT, Inc., and now has a 49.9% equity stake in the company, together with commercialisation rights to pharmaceutical applications arising from DNT technology.

Dr John Raff, the Chief Executive Officer of Starpharma, said “DNT is at the centre of the US Nanotechnology Industry and has successfully made the transition from being a research-based organization to a significant commercial enterprise. DNT has excellent prospects for substantial, ongoing grant funding in addition to the income the company is already generating from dendrimer sales. Future licence deals are also being developed, based on the company's extensive dendrimer nanotechnology patent portfolio.”

Starpharma Pooled Development Limited (ASX:SPL) is a registered pooled development fund with investments in wholly owned subsidiary biopharmaceutical companies focused on the development and application of dendrimer nanotechnologies as drugs against major diseases. Starpharma lead dendrimer product, VivaGel™ recently received clearance from the US FDA for human clinical trials. VivaGel™ is a topical microbicide gel product that has been developed for women as a preventative against the sexual transmission of HIV. It is also active in animal studies for the prevention of other sexually transmitted diseases including Genital Herpes and Chlamydia.

CONTACTS:

Dr John Raff
Chief Executive Officer
+61 3 8532 2701

Mr Ben Rogers
Company Secretary
+61 3 8532 2702

www.starpharma.com